Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of dose-escalated radiation therapy to usual care in patients with locally advanced unresectable pancreatic ductal adenocarcinoma who have received an initial 4-6 months of chemotherapy. Usual care …
Sponsor: NRG Oncology
NCT ID: NCT06958328
Sites in Michigan: - Trinity Health Saint Joseph Mercy Hospital Ann Arbor — Ann Arbor, Michigan
- University of Michigan Rogel Cancer Center — Ann Arbor, Michigan
- Trinity Health IHA Medical Group Hematology Oncology - Brighton — Brighton, Michigan
- Trinity Health Medical Center - Brighton — Brighton, Michigan
- University of Michigan - Brighton Center for Specialty Care — Brighton, Michigan
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of standard chemotherapy with or without INCB161734 in participants with metastatic pancreatic ductal adenocarcinoma (PDAC).
Sponsor: Incyte Corporation
NCT ID: NCT07522073
Sites in Michigan: - Investigative Site US006 — Ann Arbor, Michigan
- Investigative Site US010 — Detroit, Michigan
- Investigative Site US078 — Grand Rapids, Michigan
- Investigative Site US012 — Ypsilanti, Michigan
Phase 2, Phase 3 Recruiting Industry
The purpose of this study is to assess the safety and efficacy of BMS-986504, a selective, MTA-cooperative PRMT5 inhibitor, in combination with Nab-paclitaxel/Gemcitabine (nab-p/gem) versus placebo in combination with nab-p/gem, in partici…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07076121
Sites in Michigan: - Brigitte Harris Cancer Pavilion — Detroit, Michigan
- The Cancer & Hematology Centers — Grand Rapids, Michigan
Phase 2, Phase 3 Recruiting Industry
The primary purpose of this study is to assess the effectiveness of zanzalintinib compared to everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors.
Sponsor: Exelixis
NCT ID: NCT06943755
Sites in Michigan: - Exelixis Clinical Site #47 — Detroit, Michigan
- Exelixis Clinical Site #1 — Grand Rapids, Michigan
Phase 2, Phase 3 Recruiting Industry
The study is a randomized, double-blind, placebo-controlled, multicenter study of standard treatment with nab-paclitaxel and gemcitabine with or without SBP-101 in subjects previously untreated for metastatic pancreatic ductal adenocarcino…
Sponsor: Panbela Therapeutics, Inc.
NCT ID: NCT05254171
Sites in Michigan: - Henry Ford Health System — Detroit, Michigan
Phase 3 Recruiting Academic/Other
Johns Hopkins clinical research office quality assurance group will monitor and audit this study at Johns Hopkins. The Sub Investigator at each site will be responsible for internal monitoring at their site.
Sponsor: Johns Hopkins University
NCT ID: NCT02000089
Sites in Michigan: - University of Michigan — Ann Arbor, Michigan
Phase 2, Phase 3 Recruiting Industry
The goal of this clinical study is to compare the efficacy and safety of OT-101 in combination with mFOLFIRINOX (folinic acid, 5-FU, irinotecan, oxaliplatin) to mFOLFIRINOX alone in patients with advanced and unresectable or metastatic pan…
Sponsor: Oncotelic Inc.
NCT ID: NCT06079346
Sites in Michigan: - Karmanos Cancer Center — Detroit, Michigan
Phase 2 Recruiting NIH
This phase II trial investigates how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic cancer that has been surgically removed (resected) and has a pathogenic mutation…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04858334
Sites in Michigan: - Hickman Cancer Center — Adrian, Michigan
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor — Ann Arbor, Michigan
- University of Michigan Rogel Cancer Center — Ann Arbor, Michigan
- Trinity Health IHA Medical Group Hematology Oncology - Brighton — Brighton, Michigan
- Trinity Health Medical Center - Brighton — Brighton, Michigan
Phase 2 Recruiting Network
This phase II trial studies the effect of capecitabine and temozolomide after surgery in treating patients with high-risk well-differentiated pancreatic neuroendocrine tumors. Chemotherapy drugs, such as capecitabine and temozolomide, work…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05040360
Sites in Michigan: - University of Michigan Comprehensive Cancer Center — Ann Arbor, Michigan
- University of Michigan - Brighton Center for Specialty Care — Brighton, Michigan
- Henry Ford Cancer Institute-Downriver — Brownstown, Michigan
- Henry Ford Hematology Oncology - Hayes — Clinton Township, Michigan
- Henry Ford Macomb Hospital-Clinton Township — Clinton Township, Michigan
Phase 2 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of adjuvant autogene cevumeran plus atezolizumab and modified leucovorin, 5-fluorouracil (5-FU), irinotecan, and oxaliplatin (mFOLFIRINOX) versus mFOLFIRINOX alone in partici…
Sponsor: Genentech, Inc.
NCT ID: NCT05968326
Sites in Michigan: - Henry Ford Health System — Detroit, Michigan
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interf…
Sponsor: Children's Oncology Group
NCT ID: NCT04851119
Sites in Michigan: - C S Mott Children's Hospital — Ann Arbor, Michigan
Phase 1, Phase 2 Recruiting Industry
This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06128551
Sites in Michigan: - Henry Ford Cancer — Detroit, Michigan
- START Midwest — Grand Rapids, Michigan
Phase 2 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with previously treated solid tumors that have Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ …
Sponsor: Jazz Pharmaceuticals
NCT ID: NCT06695845
Sites in Michigan: - Barbara Ann Karmanos Cancer Institute — Detroit, Michigan
Phase 1, Phase 2 Recruiting Industry
This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specif…
Sponsor: Tango Therapeutics, Inc.
NCT ID: NCT05732831
Sites in Michigan: - Henry Ford Cancer Center — Detroit, Michigan
Phase 1, Phase 2 Recruiting Industry
This is a study to evaluate the safety and potential anti-tumor activity of an investigational agent called ARV-806 in Adults with Advanced Cancer having a specific KRAS mutation. This is an open-label study which means that participants a…
Sponsor: Arvinas Inc.
NCT ID: NCT07023731
Sites in Michigan: - Clinical Trial Site — Grand Rapids, Michigan
Phase 1, Phase 2 Recruiting Industry
The goal of this clinical trial is to learn if an investigational drug CP-383 works to treat advanced cancer. It will also learn about the safety of CP-383. The main questions if aims to answer are: * Does CP-383 slow or stop the growth of…
Sponsor: Tasca Therapeutics
NCT ID: NCT07030257
Sites in Michigan: - START Midwest — Grand Rapids, Michigan
Phase 1, Phase 2 Recruiting Industry
This study will assess the safety and efficacy of VS-7375 alone and in combination in patients with advanced solid tumors harboring a KRAS G12D-mutation.
Sponsor: Verastem, Inc.
NCT ID: NCT07020221
Sites in Michigan: - University of Michigan — Ann Arbor, Michigan
Phase 1, Phase 2 Recruiting Industry
This is an open-label, Phase 1/2 study to determine the safety, tolerability, and efficacy of APL-5125 for the treatment of selected locally advanced or metastatic solid tumors with particular focus on Colorectal carcinoma (CRC).
Sponsor: Apollo Therapeutics Ltd
NCT ID: NCT06399757
Sites in Michigan: - University of Michigan — Ann Arbor, Michigan
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibi…
Sponsor: Medicenna Therapeutics, Inc.
NCT ID: NCT05086692
Sites in Michigan: - Karmanos Cancer Institute — Detroit, Michigan
Phase 2 Recruiting Industry
The purpose of the study is to assess the efficacy and safety of Acoustic Cluster Therapy (ACT) when given in addition to chemotherapy for treatment of Locally Advanced Pancreatic Cancer.
Sponsor: EXACT Therapeutics AS
NCT ID: NCT06850623
Sites in Michigan: - Henry Ford Centre — Detroit, Michigan
Phase 2 Recruiting Academic/Other
The goal of this study is to learn if the combination of nab-paclitaxel, gemcitabine and an Amplitude-Modulated Radiofrequency Electromagnetic Fields device (Therabionic P1) is safe and effective for patients with adenocarcinoma of the pan…
Sponsor: Barbara Ann Karmanos Cancer Institute
NCT ID: NCT06576115
Sites in Michigan: - Karmanos Cancer Institute at McLaren Clarkston — Clarkston, Michigan
- Karmanos Cancer Institute — Detroit, Michigan
- Karmanos Cancer Institute at McLaren Flint — Flint, Michigan
- Karmanos Cancer Institute at McLaren Greater Lansing — Lansing, Michigan
- Karmanos Cancer Institute at McLaren Lapeer Region — Lapeer, Michigan
Phase 2 Recruiting Industry
This is a Phase 2, single-arm study to evaluate the safety and efficacy of relacorilant in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic adenocarcinoma (PDAC).
Sponsor: Corcept Therapeutics
NCT ID: NCT07259317
Sites in Michigan: - Site 03 — Grand Rapids, Michigan
Phase 1, Phase 2 Recruiting Industry
This is a first-in-human, Phase 1/2 study to evaluate LCB84, a TROP2-directed antibody-drug conjugate, alone and in combination with an anti-PD-1 Ab, in dose escalation (Phase 1) followed by dose expansion (Phase 2). The study population i…
Sponsor: LigaChem Biosciences, Inc.
NCT ID: NCT05941507
Sites in Michigan: - University of Michigan — Ann Arbor, Michigan
Phase 1, Phase 2 Recruiting Industry
This is a multicenter, open-label, prospective Phase 1/2a study to assess safety and tolerability, establish dosimetry and to identify an optimal imaging dose (radioactivity) and imaging time window of 64Cu-LNTH-1363S, and to compare its i…
Sponsor: Lantheus Medical Imaging
NCT ID: NCT06298916
Sites in Michigan: - BAMF Health, Inc. — Grand Rapids, Michigan
Phase 2 Recruiting Network
The prognosis for patients with localized pancreatic adenocarcinoma who are not surgical candidates is poor. Patients characterized as having "borderline resectable" disease treated with preoperative chemo-radiotherapy fair somewhat better…
Sponsor: Proton Collaborative Group
NCT ID: NCT02598349
Sites in Michigan: - McLaren Proton Therapy Center — Flint, Michigan